HCPCS Code Q4081: Injection, Epoetin Alfa, 100 Units (For ESRD on Dialysis)

## **HCPCS code Q4081 documentation requirements** HCPCS code Q4081, which is for the injection of epoetin alfa (100 units) used for ESRD patients on dialysis, has specific documentation requirements primarily focused on the need to report the most recent hematocrit or hemoglobin levels. According to CMS guidelines effective January 1, 2008, all claims billing ESA administration with Q4081 must include the most recent hematocrit or hemoglobin reading available at the time the ESA dose was administered. This is critical for validating the medical necessity of the therapy, preventing unnecessary rbc transfusion, and ensuring the patient’s hemoglobin levels remain within Medicare thresholds. For institutional claims, hemoglobin and hematocrit readings are reported using specific value codes (48 for hemoglobin, 49 for hematocrit), and professional claims require including these test results in designated fields on the CMS-1500 or electronic claim forms. Failure to report the most recent hematocrit or hemoglobin results when billing with Q4081 will result in claims being returned as unprocessable by Medicare, often accompanied by adjustment and remittance advice codes that indicate incomplete or invalid information. Facilities are advised to bill at a frequency that aligns with providing the most recent relevant lab values prior to the billing period for the administrations claimed. Additionally, for ESRD-related epoetin alfa treatments, appropriate modifiers such as JA (intravenous administration) or JB (subcutaneous administration) must be included on claims to indicate the route of administration. These documentation and reporting standards ensure compliance with Medicare policies, proper adjudication of claims, and accurate reimbursement for epoetin alfa therapy in dialysis treatment settings. The detailed guidelines are published in CMS Change Requests such as CR5699 and related Medicare Claims Processing Manuals.

## **HCPCS code Q4081 billing requirements** HCPCS code Q4081, used for billing the injection of epoetin alfa (100 units) for patients with End Stage Renal Disease (ESRD) on dialysis, has specific billing requirements established by CMS. Providers must bill with the appropriate revenue codes and CPT codes for each line of service. For example, J-code Q4081 is typically billed on institutional claims (UB-04) for ESRD dialysis patients and clarify the interplay of revenue codes with ESA billing. CPT code 90999 is usually for dialysis procedures, not the injection itself; ESA administration billing is typically represented by Q-codes or J-codes. Providers should consult current Medicare policies or billing manuals to ensure matching codes. The claims should clearly identify the dialysis session date of service, and each administration of epoetin alfa must be billed as a separate line item with the number of units corresponding to the amount administered. Importantly, claims using Q4081 must include specific modifiers indicating the route of administration: JA for intravenous, JB for subcutaneous, or JE if administered via dialysate. Providers must also report the patient’s most recent hematocrit or hemoglobin values on the claims to support medical necessity; this is reported as value codes 48 (hemoglobin) or 49 (hematocrit). Claims missing these lab values are subject to being returned. The diagnosis code for ESRD, typically N18.6, should appear as the primary diagnosis on the claim. Facilities must also report condition codes related to dialysis, such as 71, 72, 73, 74, 76, 80, or 59, depending on circumstances, to provide additional context for billing. Providers should avoid submitting claims that cross billing periods or combine billing for different types of dialysis in one claim.

## **Other relevant codes** Other relevant HCPCS codes related to Q4081 for epoetin alfa include: - **Q4074**: Older code for injection, epoetin alfa, 1,000 units (for ESRD on dialysis) (older code before Q4081) - **Q4082**: Injection, epoetin alfa, biosimilar, 100 units (for ESRD on dialysis) - **Q5105**: Injection, epoetin alfa-epbx, biosimilar (Retacrit), 100 units (for ESRD on dialysis) - **J0885**: Injection, epoetin alfa, (for non-ESRD use), 1,000 units - **Q5106**: Injection, epoetin alfa-epbx, biosimilar, (Retacrit), 1,000 units (for non-ESRD use)